Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
-
Published:2023-05-03
Issue:1
Volume:13
Page:
-
ISSN:2044-5385
-
Container-title:Blood Cancer Journal
-
language:en
-
Short-container-title:Blood Cancer J.
Author:
Palandri FrancescaORCID, Elli Elena M., Auteri Giuseppe, Bonifacio MassimilianoORCID, Benevolo Giulia, Heidel Florian H., Paglia SimonaORCID, Trawinska Malgorzata M., Bosi Costanza, Rossi Elena, Tiribelli MarioORCID, Tieghi AlessiaORCID, Iurlo AlessandraORCID, Polverelli NicolaORCID, Caocci GiovanniORCID, Binotto Gianni, Cavazzini Francesco, Beggiato Eloise, Cilloni Daniela, Tatarelli Caterina, Mendicino Francesco, Miglino Maurizio, Bocchia Monica, Crugnola Monica, Mazzoni Camilla, Romagnoli Andrea D., Rindone Giovanni, Ceglie Sara, D’Addio Alessandra, Santoni Eleonora, Cattaneo Daniele, Bartoletti Daniela, Lemoli Roberto M., Krampera MauroORCID, Cuneo Antonio, Semenzato Gianpietro C.ORCID, Latagliata Roberto, Abruzzese ElisabettaORCID, Vianelli Nicola, Cavo MicheleORCID, Andriani Alessandro, De Stefano ValerioORCID, Palumbo Giuseppe A.ORCID, Breccia MassimoORCID
Funder
Ministero della Salute
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Reference15 articles.
1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45. 2. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia [Internet]. 2021;35:485–93. 3. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol [Internet]. 2021;96:145–62. 4. Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol [Internet]. 2019;9:1186. 5. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia [Internet]. 2021;35:485–93.
|
|